Drug Profile
Radspherin - Oncoinvent
Alternative Names: 224-calciumcarbonate-microparticles - Oncoinvent; 224Ra-CaCO3-MP - Oncoinvent; Alpha-emitting radionuclide therapy - Oncoinvent; Ra-224 based therapeutic - Oncoinvent; Radium-224 based therapeutic - Oncoinvent; Radspherin®Latest Information Update: 04 Apr 2024
Price :
$50
*
At a glance
- Originator Oncoinvent
- Class Antineoplastics; Radioisotopes; Radiopharmaceuticals; Small molecules
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Colorectal cancer
- Phase I Ovarian cancer
Most Recent Events
- 04 Apr 2024 Oncoinvent plans a phase III trial for Colorectal cancer
- 31 Oct 2023 US FDA approves IND application for Radspherin in Ovarian cancer (peritoneal carcinomatosis from ovarian cancer)
- 31 Oct 2023 Oncoinvent plans a phase IIb trial for Ovarian cancer (First-line therapy) in USA (Intraperitoneal) by Q2 2024